JOHNSON B, STEVENS T, BOUCHILLON S, JOHNSON J, HOBAN D, GAYLORD C, HACKEL M, MCCARTHY M, PERSON M; Interscience Conference on Antimicrobial Agents and Chemotherapy (43rd: 2003: Chicago, Ill.).
Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 2003 Sep 14-17; 43: abstract no. E-1536.
Laboratories International for Microbiology Studies, Inc., Schaumburg, IL.
BACKGROUND: Resistance of gram positive bacteria continue to be a therapeutic challenge for the clinician. The development of glycylcyclines, which are novel derivatives of tetracyclines, are showing promise of significant activity against many gram-positive pathogens. Tigecycline (GAR-936) is a new glycylcycline currently in development, that has been shown potent activity against Staphylococcus spp. The activity of tigecycline was compared with those of other agents against methicillin resistant Staphylococcus aureus (MRSA) and methicillin sensitive Staphylococcus aureus (MSSA) from hospitals in Europe, Middle East and South Africa. METHODS: Clinical isolates were collected between January 2001 - September 2002. A total of 499 isolates were identified to genus and species at each site and confirmed by the central laboratory. MIC's were determined by the central laboratory using broth microdilution panels from Dade Microscan according to NCCLS guidelines and manufacturer's instructions. RESULTS: The susceptibility results of the 499 isolates of Staphylococcus aureus are listed below. CONCLUSION: The in vitro activity of tigecycline was very good against both MSSA and MRSA and comparable to both vancomycin and quinupristin/dalfopristin. Tigecycline activity was superior to linezolid, imipenem and the beta-lactam antimicrobials.
Publication Types:
Keywords:
- Acetamides
- Anti-Infective Agents
- Europe
- Gram-Positive Bacteria
- In Vitro
- Microbial Sensitivity Tests
- Middle East
- Minocycline
- Oxazolidinones
- South Africa
- Staphylococcal Infections
- Staphylococcus
- Staphylococcus aureus
- Virginiamycin
- dalfopristin
- linezolid
- quinupristin
- tigecycline
Other ID:
UI: 102265936
From Meeting Abstracts